Earlier this month, a manuscript by Zaki et al. (2025) looked at the long-term safety and efficacy of esketamine nasal spray (Spravato) in treatment-resistant depression (TRD). It provides an unprecedented look at how the product is used over the medium and long term, such as average treatment duration, reasons for discontinuation, and outcomes. The data is derived…
